Drug Profile
Setmelanotide - Rhythm
Alternative Names: BIM-22493; CAM 4072; IMCIVREE; RM-493Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ipsen
- Developer Ipsen; Rhythm
- Class Amides; Cyclic peptides; Cysteines; Disulfides; Obesity therapies
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Obesity
Most Recent Events
- 29 Feb 2024 Rhythm Pharmaceuticals has multiple worldwide patents pending for melanocortin and MC4 programme as of March 2023
- 22 Feb 2024 Rhythm completes enrollment in a phase III clinical trials in Obesity (In adolescents, In adults, In children, In the elderly) in Canada, Germany, Netherlands, United States and United Kingdom (SC) (NCT05774756)
- 22 Feb 2024 Rhythm Pharmaceuticals plans to complete submission of a sNDA to the US FDA seeking a label expansion to treat pediatric patients between 2 and younger than 6 years old in Obesity in the first half of 2024